Sygnature Discovery

SEPTEMBER 25, 2023

Sygnature Discovery identifies potent SHP2 degrader compounds using its proprietary targeted protein degrader platform, CHARMED, in collaboration with Japanese specialty chemical company, UBE Corporation. UBE Corporation: www.ube.com

Targeted Protein Degradation 52

Targeted Protein Degradation Small Molecule Science Disease 52

BMG Labtech

MAY 22, 2024

Options for cell-based protein degrader assays Interest is growing in the use of targeted-protein degradation to induce the breakdown of disease-causing proteins after treatment with small molecule drugs.

Targeted Protein Degradation 52

Targeted Protein Degradation Small Molecule Treatment Disease 52

Drug Target Review

JULY 23, 2024

I studied Natural Sciences at the University of Cambridge, where I was exposed to a range of disciplines from chemistry to physiology, specialising in my last year in biochemistry. Pushing the boundaries of science always opens the door to new, impactful developments, although there are always challenges along the way.

Small Molecule 116

Small Molecule Targeted Protein Degradation Science Disease 116

Broad Institute

FEBRUARY 27, 2024

CBTS Supergroup Meetings By Rose Circeo February 27, 2024 Breadcrumb Home Chembio-Therapeutics CBTS Supergroup Meetings Regular program meetings draw participants from many research communities to share cutting-edge research and brainstorm new project ideas in a wide variety of fields relevant to chemical biology and therapeutics science.

Targeted Protein Degradation 52

Targeted Protein Degradation DNA Engineering Science 52

BMG Labtech

APRIL 16, 2024

Promising future Molecular glues offer exciting opportunities for targeted protein degradation and new ways to reach some of the estimated 85% of undruggable targets in the proteome. 2 Close cousins Both molecular glues and PROteolysis TArgeting Chimeras ( PROTACs ) are targeted-protein degraders.

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Drug Development Disease 40

The Pharma Data

OCTOBER 15, 2020

a leading biotechnology company developing small molecule therapeutics based on its proprietary uSMITE platform of targeted protein degradation technology, today announced that the company’s internal program to develop selective degraders that target key proteins within the TRK family has been published by the Journal of Medicinal Chemistry. “In

Targeted Protein Degradation 40

Targeted Protein Degradation Small Molecule Science Disease 40

Drug Target Review

OCTOBER 4, 2023

He holds a PhD in Biomedical Sciences from Queen’s University of Belfast (Northern Ireland). Science 261 , 212–215 (1993). Antibody–PROTAC Conjugates Enable HER2-Dependent Targeted Protein Degradation of BRD4 | ACS Chemical Biology. References Trail PA, et al. Florian S, Mitchison TJ. Anti-Microtubule Drugs.

Small Molecule 126

Small Molecule Drugs Immune Response Targeted Protein Degradation 126

The Pharma Data

JULY 22, 2021

This collaboration has the potential to be transformational, as it combines our leadership in targeted protein degradation with Pfizer’s global capabilities and deep expertise in breast cancer. The companies will equally share worldwide development costs, commercialization expenses, and profits.

Targeted Protein Degradation 52

Targeted Protein Degradation Therapies Clinical Trials Treatment 52

The Pharma Data

SEPTEMBER 15, 2020

The companies will receive priority admission or renewal for one year of lab bench space with access to core facilities at the MBC BioLabs life sciences incubator, including access to Amgen ‘s scientific experts and business leaders to help advance their scientific programs.

Targeted Protein Degradation 52

Targeted Protein Degradation Molecular Biology Small Molecule Science 52

Elrig

MARCH 22, 2023

ELRIG will be partnering with EU-OPENSCREEN, Europe’s open-access infrastructure for chemical biology research; the Division of Chemistry in Life Sciences of the European Chemical Society; and AstraZeneca, who will be hosting the event in their Gothenburg R&D building. The symposium provides a unique opportunity to do that.”

Targeted Protein Degradation 40

Targeted Protein Degradation Science Disease Laboratories 40

Drug Hunter

AUGUST 21, 2023

Putting it All Together: A Complete Campaign Example from Novartis (NIBR) One case study from Novartis that has previously been highlighted in Molecules of the Month is a HAT program targeting the proteosome. Figure 18. A) Progression of a Novartis HAT program from a screening hit to brain-penetrant leads.

Drugs 206

Drugs Disease Targeted Protein Degradation Screening Hits 206

LifeSciVC

OCTOBER 28, 2024

In part a reasonable and justified reaction to the over-hyped “big science project” platforms funded during the pandemic bubble, this sentiment needs to considered in the context of how the innovation pendulum swings back and forth over cycles. Today’s common refrain around “assets-in, platforms-out” is pervasive.

Licensing 91

Licensing Licensing Marketing Targeted Protein Degradation 91

LifeSciVC

FEBRUARY 5, 2025

However, in recent years, huge leaps have been made in drug discovery ranging from novel technologies unearthing new techniques for small molecule development to new modalities like targeted protein degradation that are beginning to open the door to a promising wave of transcription factor-directed therapeutic candidates.

Small Molecule 67

Small Molecule Targeted Protein Degradation Regulations Disease 67